Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Accured Expenses (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Change in Accured Expenses for 5 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 22.68% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Dec 2025, up 161.62% year-over-year, with the annual reading at $14.1 million for FY2025, 161.62% up from the prior year.
  • Change in Accured Expenses hit $5.8 million in Q4 2025 for Krystal Biotech, down from $5.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q4 2024 to a low of -$5.2 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $1.6 million across 5 years, with a median of $2.0 million in 2022.
  • Biggest five-year swings in Change in Accured Expenses: surged 629.35% in 2022 and later crashed 272.03% in 2023.
  • Year by year, Change in Accured Expenses stood at -$4.0 million in 2021, then skyrocketed by 153.64% to $2.2 million in 2022, then surged by 70.75% to $3.7 million in 2023, then skyrocketed by 103.18% to $7.5 million in 2024, then fell by 22.68% to $5.8 million in 2025.
  • Business Quant data shows Change in Accured Expenses for KRYS at $5.8 million in Q4 2025, $5.9 million in Q3 2025, and -$1.3 million in Q2 2025.